ProCore Bio Med is a biotechnology company developing cost-effective solutions with a focus on bone and cartilage regeneration, integrating proprietary scaffolds, growth factors, and stem or progenitor cells. The companys technology platform includes a variety of biomaterials useful for multiple clinical applications, in particular hyaluronic acid-based injectable hydrogels; a set of proprietary growth factors with enhanced activity, selectivity, and stability; and protocols for stem and progenitor cell isolation, expansion, and differentiation. ProCores RegenoGel is a highly stable viscosupplement gel for treating osteoarthritis to preserve joints and regenerate cartilage. RegenoGel is based on the companys proprietary HAProLink, which joins a high-molecular-weight HA with a regenerative fibrinogen matrix. ProCore has been a principal member of the Genesis consortium, the Israeli consortium for stem cell therapy. Procore was acknowledged for its contributions to the consortium, including allowing access to its proprietary set of FGF variants, as well as for its unique stem cell platform and the development of a novel antibody microarray for stem cell characterization.